Corcept Therapeutics (CORT) Tops Q2 EPS by 10c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.85 +0.18%
EPS Growth %: -96.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -96.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.29, $0.10 better than the analyst estimate of $0.19. Revenue for the quarter came in at $194.4 million versus the consensus estimate of $199.4 million.
GUIDANCE:
Corcept Therapeutics sees FY2025 revenue of $850-900 million, versus the consensus of $899 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- Cerebras Q1 EPS miss sends shares down 9% after-hours
- After-Hours Stock Movers: FDX, CBRS, NKE
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
